Johnson & Johnson (NYSE:JNJ) is listed among the 15 Best Passive Income Stocks to Buy Right Now. Scotiabank’s Louise Chen began coverage of large-cap biopharma companies, emphasizing the potential for innovation in curing diseases. JNJ’s dividend record is unmatched, with steady growth despite challenges, reaching $24 billion in third-quarter sales. The company focuses on Innovative Medicine and MedTech globally. While JNJ is a solid investment, some AI stocks may offer greater returns with less risk. Check out the best short-term AI stock for potential upside.

Read more at Yahoo Finance: Johnson & Johnson (JNJ) Emerges as Scotiabank’s Top Pick for Curative Treatments